{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Peritoneal+Mesothelioma%2C+Advanced", "query": { "condition": "Malignant Peritoneal Mesothelioma, Advanced" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 22, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Peritoneal+Mesothelioma%2C+Advanced&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-25T19:18:15.687Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00024271", "title": "Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Mesothelioma" ], "interventions": [ { "name": "recombinant interferon gamma", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "mitomycin C", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "hyperthermia treatment", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Herbert Irving Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-06", "last_synced_at": "2026-06-25T19:18:15.687Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024271" }, { "nct_id": "NCT00066651", "title": "Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer", "Fallopian Tube Cancer", "Head and Neck Cancer", "Lung Cancer", "Malignant Mesothelioma", "Ovarian Cancer", "Pancreatic Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "SS1(dsFv)-PE38 immunotoxin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2003-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-06-25T19:18:15.687Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Winston-Salem, North Carolina", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066651" }, { "nct_id": "NCT05337735", "title": "A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Microsatellite High Cancers", "Peritoneal Mesothelioma", "Extrapulmonary High Grade", "Neuroendocrine Carcinomas", "Cervical Carcinoma", "Hodgkin's Lymphoma", "Pleural Mesothelioma", "Small Cell Lung Cancer" ], "interventions": [ { "name": "XmAb20717", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 140, "start_date": "2022-08-05", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-06-25T19:18:15.687Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05337735" }, { "nct_id": "NCT03507452", "title": "First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma", "Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma", "Advanced Recurrent Serous Ovarian Cancer", "Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)" ], "interventions": [ { "name": "BAY2287411", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2018-06-13", "completion_date": "2022-03-29", "has_results": false, "last_update_posted_date": "2023-03-20", "last_synced_at": "2026-06-25T19:18:15.687Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Houston, Texas", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03507452" }, { "nct_id": "NCT05451849", "title": "A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mesothelioma", "Mesotheliomas Pleural", "Mesothelioma, Malignant", "Mesothelioma Peritoneum", "Ovarian Cancer", "Ovarian Serous Adenocarcinoma", "Pancreatic Cancer", "Pancreatic Adenocarcinoma", "Colorectal Cancer", "Triple Negative Breast Cancer", "TNBC - Triple-Negative Breast Cancer", "Ovarian Adenocarcinoma", "Pancreatic Neoplasms", "Colorectal Neoplasms", "Ovarian Neoplasms", "Cholangiocarcinoma", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "TC-510", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "TCR2 Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2022-06-21", "completion_date": "2028-10-30", "has_results": false, "last_update_posted_date": "2025-08-27", "last_synced_at": "2026-06-25T19:18:15.687Z", "location_count": 7, "location_summary": "San Francisco, California • Miami, Florida • Bethesda, Maryland + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05451849" }, { "nct_id": "NCT00020579", "title": "MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "entinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2001-03", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-06-25T19:18:15.687Z", "location_count": 3, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020579" }, { "nct_id": "NCT00003034", "title": "ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Malignant Mesothelioma" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "ranpirnase", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alfacell", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 300, "start_date": "1997-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-11-06", "last_synced_at": "2026-06-25T19:18:15.687Z", "location_count": 7, "location_summary": "South Bend, Indiana • Baltimore, Maryland • Grand Rapids, Michigan + 4 more", "locations": [ { "city": "South Bend", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Duluth", "state": "Minnesota" }, { "city": "Saint Charles", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003034" }, { "nct_id": "NCT07277413", "title": "A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NSCLC Adenocarcinoma", "Gastroesophageal Cancer (GC)", "Gastric Adenocarcinoma", "Adenocarcinoma of Esophagus", "Squamous Cell Car. - Esophagus", "Urothelial Carcinoma (UC)", "Bladder Cancer", "Mesothelioma", "Pleural Mesothelioma", "Peritoneal Mesothelioma", "Non-Small Cell Lung Cancer NSCLC", "Pancreatic Cancer", "Biliary Tract Carcinoma" ], "interventions": [ { "name": "IDE892", "type": "DRUG" }, { "name": "IDE397", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IDEAYA Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2026-03-04", "completion_date": "2028-04-30", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-06-25T19:18:15.687Z", "location_count": 14, "location_summary": "Santa Rosa, California • Orlando, Florida • Omaha, Nebraska + 10 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07277413" }, { "nct_id": "NCT05086692", "title": "A Beta-only IL-2 ImmunoTherapY Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Unresectable Solid Tumor", "Clear Cell Renal Cell Carcinoma", "Triple Negative Breast Cancer", "Non-Small Cell Lung Cancer Squamous", "Non-Small Cell Lung Cancer Non-squamous", "Colorectal Cancer (MSI-H)", "Gastric Cancer", "Cervical Cancer", "Basal Cell Carcinoma", "Bladder Cancer", "Merkel Cell Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Cutaneous Squamous Cell Carcinoma", "Pleural Mesothelioma", "Esophageal Cancer", "Endometrial Carcinoma", "Solid Tumor", "Solid Tumor, Adult", "MSI-H Solid Malignant Tumor", "Cancer With A High Tumor Mutational Burden", "Epithelial Ovarian Carcinoma", "Primary Peritoneal Cancer", "Gastroesophageal Junction (GEJ) Cancer", "Acral Melanoma", "Mucosal Melanoma", "Cutaneous Melanoma", "DMMR Solid Malignant Tumor", "Fallopian Tube Cancer", "Ovarian Cancer", "MSI-H Cancer", "DMMR Cancer", "Pancreas Adenocarcinoma (MSI-H)", "Skin Cancer", "Viral Cancer", "Cervical Cancers", "Endometrial Cancer" ], "interventions": [ { "name": "MDNA11", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medicenna Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2021-08-27", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2025-07-09", "last_synced_at": "2026-06-25T19:18:15.687Z", "location_count": 7, "location_summary": "San Diego, California • San Francisco, California • Santa Monica, California + 4 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05086692" }, { "nct_id": "NCT00006981", "title": "Immunotoxin Therapy in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer", "Fallopian Tube Cancer", "Head and Neck Cancer", "Lung Cancer", "Malignant Mesothelioma", "Ovarian Cancer", "Pancreatic Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "SS1(dsFv)-PE38 immunotoxin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2000-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-04-30", "last_synced_at": "2026-06-25T19:18:15.687Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006981" } ] }